Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00088608 | A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease | PHASE2 | COMPLETED | 26 | — | — | Apr 1, 2004 | - | Nov 7, 2016 | 5 | United States |
| Name | Type | Description |
|---|---|---|
| SOM230 s.c. | DRUG | - |
Inclusion Criteria: * Patients with pituitary Cushing's disease within the two months prior to study entry * Patients for whom written informed consent to participate in the study has been obtained * Female patients of child bearing potential who have not undergone clinically documented total hyste...